RE:reo and t cell-based strategies" Altogether, our data indicate that NAbs hamper the oncolytic efficacy of Reo, but not its immunotherapeutic capacity. Given the high prevalence of seropositivity for Reo in cancer patients, our data strongly advocate for the application of Reo as part of T cell-based immunotherapeutic strategies. "